Term
|
Definition
| Innate (non-specific) immune response |
|
|
Term
| Monocytes, macrophages, mast cells, granulocytes, dendritic cells |
|
Definition
|
|
Term
| T helper cells and cytotoxic T cells |
|
Definition
| Adaptive (specific) immune response |
|
|
Term
| acts on major APCs to T cells |
|
Definition
|
|
Term
| release inflammatory mediators |
|
Definition
|
|
Term
| neutrophils, eosinophils, basophils |
|
Definition
|
|
Term
|
Definition
|
|
Term
| exocytosis of granules (cell lysis, apoptosis via IgE activation) |
|
Definition
|
|
Term
|
Definition
|
|
Term
| express many receptors when activated that aid in rapid antigen recognition, become APCs to T cells as well |
|
Definition
|
|
Term
| present engulfed antigen segnments/major histocompatibility complexes on their surfaces |
|
Definition
|
|
Term
| Receptors on APC that signal to CD28 receptor on TCR |
|
Definition
|
|
Term
| Recruit new macrophages, neutorphils, lymphocytes, etc |
|
Definition
|
|
Term
| Release cellular components that cause lysis, apoptosis |
|
Definition
|
|
Term
| surviving plasma cells become |
|
Definition
|
|
Term
| block cytokine activation by binding to corticosteroid response elements which inhibit synthesis of other immune response factors |
|
Definition
|
|
Term
| Inhibit T cell proliferation ---> inhibiting production of IL2 |
|
Definition
|
|
Term
| requires bile for intestinal absorption |
|
Definition
|
|
Term
|
Definition
| Prednisone, metylprednisolone |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| approved and recommended for renal transplant |
|
Definition
|
|
Term
| bind to FKBP12 forming a complex ---> blocks IL2 signal for cell growth |
|
Definition
|
|
Term
|
Definition
| mycophenolate mofetil, azathioprine |
|
|
Term
| prodrug for 6-mercatopurine, disrupts both salvage and de novo syntehssi pathyways of DNA, RNA, and protein |
|
Definition
|
|
Term
| inhibits de novo guanine syntehsis by binding inosine monophosphate dehydrogenase |
|
Definition
|
|
Term
| anti-thymocyte immune globulins |
|
Definition
|
|
Term
| bind to various lymphocyte receptors resulting in lymphocyte depletion |
|
Definition
| anti-thymocyte immune globulin |
|
|
Term
| Bind to CD25 on surface of activated T cells preventing IL2-mediated activation/proliferation of T cells |
|
Definition
|
|
Term
| AE: nephrotoxicity, neurotoxicity, HTN, hyperlipidemia, hyperglycemia |
|
Definition
| Calcineurin Inhibitors (cyclosporine, tacrolimus) |
|
|
Term
| AE: gingival hyperplasia, hirsutism |
|
Definition
| Cyclosporine (Calcineurin inhibitor) |
|
|
Term
|
Definition
| Tacrolimus (Calcineurin inhibitor) |
|
|
Term
| AE: increased appetite, mood change, insomnia, indigestion |
|
Definition
| Corticosteroids (prednisone, etc) |
|
|
Term
| AE: Hematologic-- leukopenia, anemia, thrombocytopenia, Other: hepatotoxicity, nausea, vomiting, pancreatitis, alopecia |
|
Definition
| Azathioprine (Antimetabolite) |
|
|
Term
| AE: dose-related myelosuppression, transient thrombocytopenia, leucopenia, and anemia |
|
Definition
| mTOR inhibitors (sirolimus, everolimus) |
|
|
Term
| mTOR inhibitors-- peark around 3 months of therapy |
|
Definition
| hypercholesterolemia and hypertriglyceridemia |
|
|
Term
| AE: myelosuppression, leukopenia, anemia, thrombocytopenia, anaphylaxis, hypotension, hypertension, tachycardia, dyspnea, urticaria, rash, serum sickness, infusion-related febrile illness |
|
Definition
|
|
Term
| AE: Hypersensivity reactions, infusion-related reactions |
|
Definition
|
|
Term
| AE: first-dose adverse reactions, fever, chillds, rigors, pruritus, capillary leak syndrome, pulmonary edema, aseptic meningitis |
|
Definition
|
|
